Compare IONQ Inc (IONQ) vs Novavax Inc (NVAX) Price & Performance

IONQ trades at $45.20, up 6.28% today, with a bullish technical signal from moving averages and strong resistance near $46. The company reported Q2 2026 revenue growth of 287% to $80.1 million, though it missed EPS estimates. Analyst consensus is a Buy with a $73.33 price target, reflecting optimism on quantum computing leadership.

Outlook is growth-driven but high-risk; revenue is projected to double in 2026, yet net losses exceed $1.4 billion. Key risks include profitability timeline, cash burn, and competitive pressures. Upside hinges on execution of its quantum roadmap and defense contracts, but volatility persists.

NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.

The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.